Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. It has two agents in clinical development for cancer, which includes CX-5461, a compound that activates p53 and kills cancer cells; and CX-4945, a compound that controls the growth and proliferation of cancer cells. The company was founded by Tai Sen Soong on November 16, 2012 and is headquartered in New Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company